Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s002620050484PMID 9690452PMCID PMC11037346
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant

  2005cited by this paper
• Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.

  1997cited by this paper
• Natural human anti-Gal alpha(1,3)Gal antibodies react with human mucin peptides.

  1997cited by this paper
• Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours.

  1996cited by this paper
• A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1.

  1996cited by this paper
• A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma.

  1996cited by this paper
• Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin.

  1995cited by this paper
• Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components

  1995cited by this paper
• Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients.

  1995cited by this paper
• Heterogeneity in production, secretion and glycosylation of MUC1 epithelial mucin by primary cultures of ovarian carcinoma

  1995cited by this paper
• Does pregnancy immunize against breast cancer?

  1995cited by this paper
• MUC‐1 Epithelial Tumor Mucin‐Based Immunity and Cancer Vaccines

  1995cited by this paper
• Quantitation of polymorphic epithelial mucin: a challenge for biochemists and immunologists.

  1995cited by this paper
• Phase-I study of synthetic muc1 peptides in breast-cancer.

  1995cited by this paper
• Structure of a tumor associated antigen containing a tandemly repeated immunodominant epitope.

  1995cited by this paper
• Specificity of the IgG response in mice and human breast cancer patients following immunization against synthetic sialyl-Tn, an epitope with possible functional significance in metastasis.

  1994cited by this paper
• Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients.

  1994influential reference
• Serum markers casa, cea, cyfra-21-1, msa, nse, tpa and tps in lung-cancer.

  1994cited by this paper
• Factors effecting the measurement of tumor-associated MUC1 mucins in serum.

  1994influential reference
• Human B-cell immune response to the polymorphic epithelial mucin.

  1993cited by this paper
• Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction.

  1993cited by this paper
• Circulating tumour-associated mucin concentrations, determined by the CASA assay, in healthy women.

  1993influential reference
• Synthesis of large multideterminant peptide immunogens using a poly-proline beta-turn helix motif.

  1993cited by this paper
• Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides.

  1993cited by this paper
• Structure and biology of a carcinoma-associated mucin, MUC1.

  1991cited by this paper
• Synthetic peptides reactive with anti-human milk fat globule membrane monoclonal antibodies.

  1990cited by this paper
• Tissue and tumor distribution of human polymorphic epithelial mucin

  1988cited by this paper
• Comparison of four new cell lines from patients with adenocarcinoma of the ovary.

  1979cited by this paper

• Heterogeneity and Functions of Tumor-Infiltrating Antibody Secreting Cells: Lessons from Breast, Ovarian, and Other Solid Cancers

  2022cites this paper
• Prevalence of high affinity naturally occurring IgG2 antibodies against human chorionic gonadotropin and its subunits in patients with ovarian cyst.

  2022cites this paper
• RETRACTED ARTICLE: Recent advances on applications of immunosensing systems based on nanomaterials for CA15-3 breast cancer biomarker detection

  2022cites this paper
• Characteristics of Immune Memory and Effector Activity to Cancer-Expressed MHC Class I Phosphopeptides Differ in Healthy Donors and Ovarian Cancer Patients

  2021cites this paper
• Characterisation of immune-modulating lymphocyte populations in melanoma patients

  2019cites this paper
• Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case–Control Study in Northern Sweden

  2019cites this paper
• Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort

  2018influential citation
• Binding of circulating anti-MUC1 antibody and serum MUC1 antigen in stage IV breast cancer.

  2017cites this paper
• Developmental Therapeutics for Gynecologic Cancers: An Overview

  2016cites this paper
• Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients

  2016cites this paper
• Utilising quantitative immunoproteomics to reveal differential autoantibody biomarker panels in serous ovarian cancer patients

  2015cites this paper
• This information is current as Meningioma-Associated Antigen TXNDC 16 Secretion and Immunogenicity of the Eckart

  2014cites this paper
• Genetic variants of IgG1 antibodies and FcγRIIIa receptors influence the magnitude of antibody-dependent cell-mediated cytotoxicity against prostate cancer cells

  2014cites this paper
• Secretion and Immunogenicity of the Meningioma-Associated Antigen TXNDC16

  2014cites this paper
• Detection of Cancer Biomarkers on Biosensor Surfaces

  2014cites this paper
• Lymphocyte cytosolic protein 1 is a chronic lymphocytic leukemia membrane-associated antigen critical to niche homing.

  2013cites this paper
• The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression

  2013cites this paper
• Natural and Induced Humoral Responses to MUC1

  2011influential citation
• Flow cytometry-based assay to evaluate human serum MUC1-Tn antibodies.

  2011cites this paper
• High-sensitivity detection of carbohydrate antigen 15-3 using a gold/zinc oxide thin film surface plasmon resonance-based biosensor.

  2010cites this paper
• Autoantibodies to Tumor-Associated Antigens in Epithelial Ovarian Carcinoma

  2010cites this paper
• Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies

  2010cites this paper
• Complement Factor H Autoantibodies Are Associated with Early Stage NSCLC

  2010cites this paper
• Prognostic and Diagnostic Value of Spontaneous Tumor-Related Antibodies

  2010cites this paper
• Autoantibodies to Tumor-Associated Antigens in Breast Carcinoma

  2010cites this paper
• Autoantibodies as biomarkers for ovarian cancer

  2010cites this paper
• Detection of Circulating Anti-Mucin 1 (MUC1) Antibodies in Breast Tumor Patients by Indirect Enzyme-Linked Immunosorbent Assay Using a Recombinant MUC1 Protein Containing Six Tandem Repeats and Expressed in Escherichia coli

  2010cites this paper
• Autoantibodies against tumor-related antigens: incidence and biologic significance.

  2010cites this paper
• Expression of aberrantly glycosylated Mucin‐1 in ovarian cancer

  2010cites this paper
• A systematic review of humoral immune responses against tumor antigens

  2009influential citation
• Healthy individuals have T-cell and antibody responses to the tumor antigen cyclin B1 that when elicited in mice protect from cancer

  2009cites this paper
• Immunology of gynecologic neoplasms: analysis of the prognostic significance of the immune status.

  2009cites this paper
• Current status of mucins in the diagnosis and therapy of cancer

  2009cites this paper
• Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti‐MUC1 antibody immune selection

  2008cites this paper
• Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer

  2008cites this paper
• Antigen‐specific immunotherapy of cervical and ovarian cancer

  2008cites this paper
• Cyclin B1: Abnormal Self /Tumor Antigen

  2008cites this paper
• Mucin-type O-glycosylation and its potential use in drug and vaccine development.

  2008cites this paper
• High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC).

  2007cites this paper
• Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: Relation to survival

  2007cites this paper
• Pre-existing T-cell immunity against mucin-1 in breast cancer patients and healthy volunteers

  2006cites this paper
• Conditions Associated with Antibodies Against the Tumor-Associated Antigen MUC1 and Their Relationship to Risk for Ovarian Cancer

  2005cites this paper
• Anti‐Tumor Antibodies in Ovarian Cancer

  2005cites this paper
• Inhibition of a complement regulator in vivo enhances antibody therapy in a model of mammary adenocarcinoma

  2004cites this paper
• MUC1 and the MUCs: A Family of Human Mucins with Impact in Cancer Biology

  2004cites this paper
• MUC1 immunobiology: from discovery to clinical applications.

  2004cites this paper
• Prevalence and prognostic significance of sMUC‐1 levels in plasma cell dyscrasias

  2003cites this paper
• Tissue and Serum MUC1 Mucin Detection in Breast Cancer Patients

  2003cites this paper
• MHC-UNRESTRICTED MUC1-SPECIFIC T CELL RECEPTOR FOR CANCER IMMUNOTHERAPY/GENE THERAPY

  2003cites this paper
• Circulating anti‐MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer

  2003cites this paper
• Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy

  2002cites this paper
• A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer.

  2002cites this paper
• Mucins and Immune Reactions to Mucins in Ulcerative Colitis

  2001cites this paper
• MUC1, The Renaissance Molecule

  2001cites this paper
• Detection of Circulating Mammary Mucin (MUC1) and MUC1 Immune Complexes (MUC1-CIC) in Healthy Women

  2001cites this paper
• MUC1 mucin as a target for immunotherapy of cancer: Muc1 based immunotherapeutic strategies

  2001cites this paper
• Mucin antibodies - new tools in diagnosis and therapy of cancer.

  2001cites this paper
• Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection1

  2001cites this paper
• Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women*

  2001influential citation
• Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer.

  2000influential citation
• Elevated soluble MUC 1 levels and decreased anti-MUC 1 antibody levels in patients with multiple myeloma

  2000cites this paper
• Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.

  2000cites this paper
• Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma.

  2000cites this paper
• Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n‐acetylgalactosamine (GalNAc) peptides

  2000cites this paper
• Changes in Tumorigenesis- and Angiogenesis-related Gene Transcript Abundance Profiles in Ovarian Cancer Detected by Tailored High Density cDNA Arrays

  2000cites this paper
• in patients with multiple myeloma Elevated soluble MUC 1 levels and decreased anti-MUC 1 antibody levels

  2000cites this paper
• Human MUC1 Mucin: A Multifaceted Glycoprotein

  2000cites this paper
• Special Section:Future Trendsin Vaccination: Advances in cancer vaccine development

  1999cites this paper
• Advances in cancer vaccine development.

  1999cites this paper
• Meningioma-Associated Antigen TXNDC16 Secretion and Immunogenicity of the

  year unknowncites this paper